No. 888 Yaocheng Avenue
Medical High-tech District
Taizhou
China
https://www.recbio.cn
Secteur(s): Healthcare
Secteur d’activité: Biotechnology
Employés à temps plein: 472
Nom | Titre | Payer | Exercé | Année de naissance |
---|---|---|---|---|
Dr. Yong Liu | Founder, CEO & Chairman of the Board | 3,14M | S.O. | 1973 |
Ms. Qingqing Chen | CFO, Secretary of Board & Executive Director | 2,2M | S.O. | 1983 |
Dr. Kunxue Hong | Chief Science Officer & Executive Director | 2,22M | S.O. | 1965 |
Mr. Bu Li | Chief Human Resource Officer & Executive Director | 2,19M | S.O. | 1977 |
Mr. Yang Zhou | Chief Operating Officer | S.O. | S.O. | S.O. |
Mr. Kejian Yang | Chief Technology Officer | S.O. | S.O. | S.O. |
Mr. Hongjun Zhou | Vice General Manager | S.O. | S.O. | 1981 |
Ms. Jing Wang | Chief Quality Officer | S.O. | S.O. | S.O. |
Mr. Lei Zhou | Finance controller | S.O. | S.O. | 1986 |
Ms. Yin Kwan Ho | Joint Company Secretary | S.O. | S.O. | 1978 |
Jiangsu Recbio Technology Co., Ltd., a vaccine company, engages in the research, development, and commercialization of subunit vaccines in the People's Republic of China. The company is developing vaccines for the treatment of cervical cancer, and anal and genital warts, including REC603, a recombinant human papillomavirus (HPV) 9-valent vaccine that is in phase III clinical trial; REC601 and REC602 recombinant HPV bivalent vaccines, which are in phase I clinical trials; REC604a, a recombinant HPV quadrivalent vaccine that is in pre-clinical stage; and REC604b, a recombinant HPV 9-valent vaccine that is in pre-clinical stage. It also develops ReCOV, a recombinant COVID-19 vaccine candidate that is in Phase II/III trial; R520A, a messenger ribonucleic acid COVID-19 vaccine candidate that is in pre-clinical stage; REC610, a recombinant shingles vaccine that is in Phase l clinical trial; REC607, a virus vectored adult tuberculosis vaccine that is in pre-clinical stage; REC606, a recombinant adult tuberculosis vaccine that is in pre-clinical stage; REC617, a recombinant influenza quadrivalent vaccine that is in pre-clinical stage; and REC605, a recombinant hand-foot-mouth disease quadrivalent vaccine that is in pre-clinical stage. Jiangsu Recbio Technology Co., Ltd. was founded in 2011 and is headquartered in Taizhou, the People's Republic of China.
L’ISS Governance QualityScore de Jiangsu Recbio Technology Co., Ltd. en date du S.O. est S.O.. Les scores principaux sont Audit : S.O.; Société : S.O.; Droits des actionnaires : S.O.; Compensation : S.O..